These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9683019)

  • 1. Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs.
    Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Ichihara M; Matsumoto Y
    Eur J Pharmacol; 1998 May; 350(1):87-91. PubMed ID: 9683019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time.
    Sato K; Kawasaki T; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
    Eur J Pharmacol; 1997 Nov; 339(2-3):141-6. PubMed ID: 9473127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
    Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
    Br J Pharmacol; 1998 Jan; 123(1):92-6. PubMed ID: 9484858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
    Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y
    Eur J Pharmacol; 1998 Apr; 347(2-3):231-6. PubMed ID: 9653887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time.
    Sato K; Kaku S; Hirayama F; Koshio H; Matsumoto Y; Kawasaki T; Iizumi Y
    Eur J Pharmacol; 1998 Jul; 352(1):59-63. PubMed ID: 9718268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
    Kawasaki T; Sato K; Sakai Y; Hirayama F; Koshio H; Taniuchi Y; Matsumoto Y
    Thromb Haemost; 1998 Feb; 79(2):410-6. PubMed ID: 9493600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.
    Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y; Iizumi Y
    Jpn J Pharmacol; 1998 Oct; 78(2):191-7. PubMed ID: 9829622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
    Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
    Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
    Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
    Kawasaki T; Sato K; Hirayama F; Koshio H; Taniuchi Y; Matsumoto Y
    Thromb Haemost; 1998 Apr; 79(4):859-64. PubMed ID: 9569205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals.
    Hayashi M; Matsuo A; Nakamoto H; Aisaka K
    Eur J Pharmacol; 2001 Jan; 412(1):61-6. PubMed ID: 11166737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
    Hirayama F; Koshio H; Katayama N; Kurihara H; Taniuchi Y; Sato K; Hisamichi N; Sakai-Moritani Y; Kawasaki T; Matsumoto Y; Yanagisawa I
    Bioorg Med Chem; 2002 May; 10(5):1509-23. PubMed ID: 11886813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
    Gustafsson D; Elg M; Lenfors S; Börjesson I; Teger-Nilsson AC
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):69-79. PubMed ID: 8845466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig.
    Himber J; Refino CJ; Burcklen L; Roux S; Kirchhofer D
    Thromb Haemost; 2001 Mar; 85(3):475-81. PubMed ID: 11307818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
    Heran C; Morgan S; Kasiewski C; Bostwick J; Bentley R; Klein S; Chu V; Brown K; Colussi D; Czekaj M; Perrone M; Leadley R
    Eur J Pharmacol; 2000 Feb; 389(2-3):201-7. PubMed ID: 10688985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis.
    Wong PC; Crain EJ; Nguan O; Watson CA; Racanelli A
    Thromb Res; 1996 Jul; 83(2):117-26. PubMed ID: 8837310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN; Girard D; Lochot S; Lecoffre C
    Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice.
    Iwatsuki Y; Kawasaki T; Hayashi K; Moritani Y; Nii T; Miyata K
    Thromb Haemost; 2004 Dec; 92(6):1221-8. PubMed ID: 15583727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.